Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 15, 2015
Grant Date -
Mar 19, 2015
app pub date -
Sep 23, 2014
filing date -
Sep 7, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully